世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

プレシジョンメディシンの市場規模、シェア、動向分析レポート:用途別((診断(遺伝子検査、エソテリック検査)、治療(医薬品、医療機器))、最終用途別、地域別、セグメント別予測、2023年~2030年


Precision Medicine Market Size, Share & Trends Analysis Report By Application ((Diagnostics (Genetic Tests, Esoteric Tests), Therapeutics (Pharmaceuticals, Medical Devices)), By End Use, By Region, And Segment Forecasts, 2023 - 2030

精密医療市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界の精密医療市場規模は、2023年から2030年にかけて年平均成長率10.7%で成長し、2030年には1,607億8,000万米ドルに達すると予... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年10月25日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報・注文方法はこちら
145 英語

本レポートは受注生産のため、ご納品のお時間をいただく場合がございます。


 

サマリー

精密医療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の精密医療市場規模は、2023年から2030年にかけて年平均成長率10.7%で成長し、2030年には1,607億8,000万米ドルに達すると予測されている。費用対効果の高いゲノム・分子生物学的検査法の導入、癌や希少疾患の有病率の増加、精密医療におけるビッグデータ利用の高まりなどの傾向は、市場成長を後押しする主要因の一部である。

ヒトゲノムプロジェクトは、全ゲノム配列決定や標的配列決定などの素晴らしい最先端技術を導入した。これらの技術は、ゲノムの研究や、様々な病気の治療のための個別化治療の創出のために研究者によって使用されている。今日、腫瘍学、免疫学、神経学などの分野における疾患の流行は、世界中で急速に増加している。

研究者、医療専門家、大手製薬会社やバイオテクノロジー企業は、患者の健康のために新たな重点治療オプションを認識するために協力している。現在、さまざまな種類のがんを治療するために、多くの治療法や薬剤が臨床試験中である。さらに、研究者たちは、がん以外の疾患領域における精密医薬品や診断法の開発にも関心を示している。

治療とは別に、診断分野もここ数年で急成長を遂げている。次世代シーケンシング(NGS)、バイオマーカー、コンパニオン診断、難解な検査の使用は、医薬品の処方パターンを変化させ、影響を与える可能性がある。個別化された医薬品は、今後20年以内に大成功を収める可能性が非常に高く、以前は不可能であった少数の頑固な病気を治療・治癒する能力を持っている。

この分野の成長には、政府や規制機関の関与が非常に重要な役割を果たしている。2015年、当時の米国政府は「プレシジョン・メディシン・イニシアティブ」の立ち上げを発表した。その翌年、中国は「中国精密医療イニシアティブ」を立ち上げた。これは15年計画で、同国を精密治療開発のリーダーとして構築することを目的としている。

現在、バイオテクノロジー企業や製薬企業の改善パイプラインにある医薬品の40%以上がバイオマーカーを組み込んでいる。同概要では、過去5年間にいくつかのバイオ製薬企業が共同事業やジョイントベンチャーを行っており、今後数年間も継続する見込みであることも推奨している。このように、診断・治療精密医療市場は計り知れない可能性を秘めており、急速に患者ケアの基本的な分野へと変貌しつつある。

精密医療市場レポートハイライト

- 遺伝子配列決定、バイオマーカー、ビッグデータ解析、コンパニオン診断などの技術が、今後数年間この市場を牽引すると予想される。

- エンドユース別では、臨床検査室が2022年の市場で圧倒的なシェアを占める。一方、在宅医療検査分野は、その迅速性、効率性、利便性により急成長を遂げている。

- 適応領域別では、がん領域の治療用精密医薬品が2022年に最大の市場シェアを占めた。しかし、非腫瘍性疾患に対する精密医薬品の開発へと研究者の焦点が変わってきている。その結果、免疫疾患、遺伝性疾患、希少疾患への注目が高まっている。

- 北米市場は現在最大のシェアを占めており、予測期間中にさらに成長すると予想される。同市場は主に、政府による支援政策やイニシアティブ、市場プレイヤーの強力なプレゼンスによって牽引されている。アジア太平洋地域は、この市場で最も急成長している地域となる見込みである。

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Application
1.1.2. End-use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application outlook
2.2.2. End-use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Precision Medicine Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Precision Medicine Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Precision Medicine: Application Estimates & Trend Analysis
4.1. Precision Medicine Market: Key Takeaways
4.2. Precision Medicine Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Diagnostics
4.3.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2. Genetic tests
4.3.2.1. Genetic tests market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3. Direct to consumer tests
4.3.3.1. Direct to consumer tests market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4. Esoteric tests
4.3.4.1. Esoteric tests market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.5. Others
4.3.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Therapeutics
4.4.1. Therapeutics market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Pharmaceuticals
4.4.2.1. Pharmaceuticals market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.2. Oncology
4.4.2.2.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.3. Respiratory diseases
4.4.2.3.1. Respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.4. Skin diseases
4.4.2.4.1. Skin diseases market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.5. CNS disorders
4.4.2.5.1. CNS disorders market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.6. Immunology
4.4.2.6.1. Immunology market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.7. Genetic diseases
4.4.2.7.1. Genetic diseases market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.8. Others
4.4.2.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Medical Devices
4.4.3.1. Medical Devices market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Precision Medicine: End Use Estimates & Trend Analysis
5.1. Precision Medicine Market: Key Takeaways
5.2. Precision Medicine Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Home Care
5.3.1. Home care market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Hospitals
5.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Clinical Laboratories
5.5.1. Clinical laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Precision Medicine Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Precision Medicine Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. F. Hoffmann-La Roche Ltd.-Foundation Medicine
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Siemens Healthineers
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Janssen Pharmaceuticals
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Illumina
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Quest Diagnostics Incorporated.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. 23andMe, Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. NeoDiagnostix, Inc.,
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. IBM Watson
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Myriad Genetics Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Medtronic
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. GE Healthcare
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Abbott Laboratories
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Dako A/S
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. Biogen
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
7.2.15. Precision Biologics Incorporated
7.2.15.1. Company overview
7.2.15.2. Financial performance
7.2.15.3. Product benchmarking
7.2.15.4. Strategic initiatives
7.2.16. Qiagen Incorporated
7.2.16.1. Company overview
7.2.16.2. Financial performance
7.2.16.3. Product benchmarking
7.2.16.4. Strategic initiatives

 

ページTOPに戻る


 

Summary

Precision Medicine Market Growth & Trends

The global precision medicine market size is expected to reach USD 160.78 billion by 2030 growing at a CAGR of 10.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. Trends such as introduction of cost-effective genomic and molecular biology testing methods, increasing prevalence of cancer and rare diseases, and rising use of big data in precision medicine are some of the key factors boosting market growth.

The Human Genome Project introduced some marvelous cutting-edge techniques such as whole genome sequencing and targeted sequencing. These technologies are being used by researchers for the study of genomes and creation of personalized therapies for treatment of various illnesses. Today, the prevalence of diseases in areas such as oncology, immunology, and neurology has rapidly increased across the globe.

Researchers, healthcare professionals, and big pharma and biotech companies are working together to recognize new focused treatments options for the wellbeing of patients. Currently, there are many therapies and drugs under clinical trials for treatment of different types of cancers. Moreover, researchers have also shown an inclination toward development of precision medicines and diagnostics in non-oncologic disease areas.

Apart from therapeutics, the diagnostics field has also witnessed rapid growth in the past few years. The use of next generation sequencing (NGS), biomarkers, companion diagnostics, and esoteric tests can possibly change and affect prescription patterns of pharmaceutical medicines. Personalized medicines have very high chances of becoming a massive success in the next 20 years and have the capacity to treat and cure a few obstinate illnesses, which was not possible before.

Involvement of government and regulatory bodies has played a very important role in the growth of this field. In 2015, the then U.S. government announced the launch of the Precision Medicine Initiative. The following year, China launched the China Precision Medicine Initiative, which is a 15-year project that aims to build the country as a leader in development of precision therapies.

At present, more than 40% of the medications in biotech and pharmaceutical companies’ improvement pipeline incorporate biomarkers. The overview likewise recommended that some biopharmaceutical organizations have collaborated and joint their ventures in the past five years and are expected to continue doing so in the coming years. The diagnostic and therapeutic precision medicine market thus holds immense potential and is quickly turning into a fundamental segment of patient care.

Precision Medicine Market Report Highlights

• Technologies such as gene sequencing, biomarkers, big data analytics, and companion diagnostics are anticipated to drive this market in the coming years

• By end use, clinical labs held the dominant share in the market in 2022. The home care testing segment, on the other hand, has been witnessing rapid growth due to its speed, efficiency, and convenience

• On the basis of indication area, therapeutic precision medicines for oncology held the largest market share in 2022. However, there has been a change in focus of researchers toward the development of precision medicines for non-oncologic diseases. This has resulted in greater focus on immunological, genetic, and rare diseases

• The North America market currently holds the largest share and is expected to grow further during the forecast period. The market is primarily driven by supportive policies and initiatives by the government and strong presence of market players. Asia Pacific is expected to emerge as the fastest growing region in this market



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Application
1.1.2. End-use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application outlook
2.2.2. End-use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Precision Medicine Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Precision Medicine Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Precision Medicine: Application Estimates & Trend Analysis
4.1. Precision Medicine Market: Key Takeaways
4.2. Precision Medicine Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Diagnostics
4.3.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2. Genetic tests
4.3.2.1. Genetic tests market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3. Direct to consumer tests
4.3.3.1. Direct to consumer tests market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4. Esoteric tests
4.3.4.1. Esoteric tests market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.5. Others
4.3.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Therapeutics
4.4.1. Therapeutics market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Pharmaceuticals
4.4.2.1. Pharmaceuticals market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.2. Oncology
4.4.2.2.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.3. Respiratory diseases
4.4.2.3.1. Respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.4. Skin diseases
4.4.2.4.1. Skin diseases market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.5. CNS disorders
4.4.2.5.1. CNS disorders market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.6. Immunology
4.4.2.6.1. Immunology market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.7. Genetic diseases
4.4.2.7.1. Genetic diseases market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2.8. Others
4.4.2.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Medical Devices
4.4.3.1. Medical Devices market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Precision Medicine: End Use Estimates & Trend Analysis
5.1. Precision Medicine Market: Key Takeaways
5.2. Precision Medicine Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Home Care
5.3.1. Home care market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Hospitals
5.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Clinical Laboratories
5.5.1. Clinical laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Precision Medicine Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Precision Medicine Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. F. Hoffmann-La Roche Ltd.-Foundation Medicine
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Siemens Healthineers
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Janssen Pharmaceuticals
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Illumina
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Quest Diagnostics Incorporated.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. 23andMe, Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. NeoDiagnostix, Inc.,
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. IBM Watson
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Myriad Genetics Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Medtronic
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. GE Healthcare
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Abbott Laboratories
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Dako A/S
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. Biogen
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
7.2.15. Precision Biologics Incorporated
7.2.15.1. Company overview
7.2.15.2. Financial performance
7.2.15.3. Product benchmarking
7.2.15.4. Strategic initiatives
7.2.16. Qiagen Incorporated
7.2.16.1. Company overview
7.2.16.2. Financial performance
7.2.16.3. Product benchmarking
7.2.16.4. Strategic initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

Grand View Research 社の最新刊レポート


よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/07/05 10:26

162.17 円

175.82 円

209.73 円

ページTOPに戻る